Scientists have made a discovery which could lead to the first change in standard liver cancer treatment in 20 years. Two ...
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...
The advent of immunotherapy based on immune checkpoint inhibitors has improved the treatment of advanced hepatocellular ...
FYB-206 is under development for the treatment of malignant melanoma (black skin cancer) and non-small cell lung cancer. The drug candidate is a pembrolizumab biosimilar. It acts by targeting ...
Unlike existing and first-generation immunotherapies that exclusively target immune T cells, these monoclonal antibodies are engineered to precise ...
Multi-centre trial evaluating efti in combination with pembrolizumab and chemotherapy in patients with non-small cell lung ...
Potential practice-changing therapies in gynecologic cancer include the emergence of carboplatin, paclitaxel, and PD-1 ...
The past 12 months have seen the FDA approvals of enfortumab vedotin plus pembrolizumab for patients with locally advanced or ...
PD-1 x VEGF antibodies show potential to surpass checkpoint inhibitors as standard-of-care in multiple oncology indications • ...
LUND, SWEDEN / ACCESSWIRE / January 8, 2025 / BioInvent International (STO:BINV)BI-1910 single agent Phase 1 Part A dose escalation has been completed and reached a biologically active dose level. Dat ...
James “Jimmy” Carter, the 39th President of the United States, passed away last week on December 29, after 22 months in Hospice care. At | Cancer ...
Hoag physicians testing promising options for the diagnosis and treatment of glioblastoma (GBM), the deadliest form of brain cancer The LIBERATE study (NCT05383872), sponsored by INSIGHTEC, evaluates ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback